| Ytd | 54.13% | |
| 1y | 54.30% |
| Open | 14.31 | Prev Close | 14.34 | Low | 13.77 | High | 14.48 | Mkt Cap | 816.38M |
| Vol | 1.10M | Avg Vol | 1.56M | EPS | 2.01 | P/E | 6.87 | Forward P/E | -22.00 |
| Beta | 1.93 | Short Ratio | 6.51 | Inst. Own | 54.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 11.49 | 200-d Avg | 9.79 | 1yr Est | 20.00 |
ZVRA News
HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o
Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and rais
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises
BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the p
Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy a
Citizens analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform
Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overwe
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041Separately filed pa